JP2007500233A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007500233A5 JP2007500233A5 JP2006533430A JP2006533430A JP2007500233A5 JP 2007500233 A5 JP2007500233 A5 JP 2007500233A5 JP 2006533430 A JP2006533430 A JP 2006533430A JP 2006533430 A JP2006533430 A JP 2006533430A JP 2007500233 A5 JP2007500233 A5 JP 2007500233A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- composition
- solution
- hydroxy
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 7
- 239000000243 solution Substances 0.000 claims 7
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- -1 2-furanylcarbonyl Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 238000000113 differential scanning calorimetry Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 239000002798 polar solvent Substances 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 238000000862 absorption spectrum Methods 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910017053 inorganic salt Inorganic materials 0.000 claims 1
- QQPHRRSYJMOQOC-DKIIUIKKSA-N n-[2-hydroxy-5-[(1r)-1-hydroxy-2-[2-[4-[[(2r)-2-hydroxy-2-phenylethyl]amino]phenyl]ethylamino]ethyl]phenyl]formamide;hydrochloride Chemical compound Cl.C1([C@@H](O)CNC2=CC=C(C=C2)CCNC[C@H](O)C=2C=C(NC=O)C(O)=CC=2)=CC=CC=C1 QQPHRRSYJMOQOC-DKIIUIKKSA-N 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47342303P | 2003-05-27 | 2003-05-27 | |
| PCT/US2004/016602 WO2004106279A2 (en) | 2003-05-27 | 2004-05-26 | CRYSTALLINE FORM OF β2 ADRENERGIC RECEPTOR AGONIST |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007500233A JP2007500233A (ja) | 2007-01-11 |
| JP2007500233A5 true JP2007500233A5 (enExample) | 2007-07-05 |
Family
ID=33490599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006533430A Pending JP2007500233A (ja) | 2003-05-27 | 2004-05-26 | β２アドレナリン作動性レセプターアゴニストの結晶形態 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US7557247B2 (enExample) |
| EP (1) | EP1641744A2 (enExample) |
| JP (1) | JP2007500233A (enExample) |
| KR (1) | KR20060017616A (enExample) |
| CN (1) | CN100528835C (enExample) |
| AR (1) | AR045317A1 (enExample) |
| AU (1) | AU2004243304A1 (enExample) |
| BR (1) | BRPI0410705A (enExample) |
| CA (1) | CA2525839A1 (enExample) |
| CO (1) | CO5650226A2 (enExample) |
| IS (1) | IS8111A (enExample) |
| MA (1) | MA27779A1 (enExample) |
| MX (1) | MXPA05012678A (enExample) |
| NO (1) | NO20056132L (enExample) |
| NZ (1) | NZ543355A (enExample) |
| RU (1) | RU2005140652A (enExample) |
| TW (1) | TW200510277A (enExample) |
| WO (1) | WO2004106279A2 (enExample) |
| ZA (1) | ZA200510104B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA73965C2 (en) * | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| TW200510277A (en) * | 2003-05-27 | 2005-03-16 | Theravance Inc | Crystalline form of β2-adrenergic receptor agonist |
| TW200526547A (en) * | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
| TW200531692A (en) * | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| US7846973B2 (en) * | 2004-04-02 | 2010-12-07 | Theravance, Inc. | Chemical process and new crystalline form |
| EP1786762A2 (en) * | 2004-09-10 | 2007-05-23 | Theravance, Inc. | Amidine substituted aryl aniline compounds |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| ES2265276B1 (es) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| EA030606B1 (ru) | 2006-05-04 | 2018-08-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Способы приготовления лекарственного средства, содержащего полиморфы |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| US8420286B2 (en) * | 2008-03-27 | 2013-04-16 | Xerox Corporation | Toner process |
| US8367294B2 (en) * | 2008-03-27 | 2013-02-05 | Xerox Corporation | Toner process |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| MX2011002558A (es) | 2008-09-10 | 2011-04-26 | Boehringer Ingelheim Int | Terapia de combinacion para el tratamiento de diabetes y estados relacionados. |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| CN102256976A (zh) | 2008-12-23 | 2011-11-23 | 贝林格尔.英格海姆国际有限公司 | 有机化合物的盐形式 |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| EP2228368A1 (en) | 2009-03-12 | 2010-09-15 | Almirall, S.A. | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one |
| EA034869B1 (ru) | 2009-11-27 | 2020-03-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин |
| KR101819609B1 (ko) | 2010-05-05 | 2018-01-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법 |
| KR20230051307A (ko) | 2010-06-24 | 2023-04-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| MX366629B (es) | 2011-07-15 | 2019-07-17 | Boehringer Ingelheim Int | Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas. |
| EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
| EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| JP6218811B2 (ja) | 2012-05-14 | 2017-10-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2015128453A1 (en) | 2014-02-28 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Medical use of a dpp-4 inhibitor |
| US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US676793A (en) * | 1899-09-12 | 1901-06-18 | A D Fenwick Machine Co | Pasting-machine for collars, &c. |
| US654117A (en) * | 1899-11-29 | 1900-07-17 | Henry B Maddocks | Coal-bucket. |
| US4064125A (en) * | 1976-10-29 | 1977-12-20 | E. R. Squibb And Sons, Inc. | Substituted amides having antiinflammatory activity |
| IL63968A (en) * | 1980-10-01 | 1985-10-31 | Glaxo Group Ltd | Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it |
| HU196775B (en) * | 1986-08-05 | 1989-01-30 | Richter Gedeon Vegyeszet | Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances |
| US5290815A (en) | 1989-09-07 | 1994-03-01 | Glaxo Group Limited | Treatment of inflammation and allergy |
| US5872126A (en) | 1996-09-06 | 1999-02-16 | Merck & Co., Inc. | Methods and compositions for treating preterm labor |
| GB9713819D0 (en) | 1997-06-30 | 1997-09-03 | Glaxo Group Ltd | Method of reducing the systemic effects of compounds |
| SE9704644D0 (sv) | 1997-12-12 | 1997-12-12 | Astra Ab | New use |
| US6350738B1 (en) * | 1998-03-06 | 2002-02-26 | Brigham Young University | Steroid derived antibiotics |
| US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US6683115B2 (en) | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
| UA73965C2 (en) | 1999-12-08 | 2005-10-17 | Theravance Inc | b2 ADRENERGIC RECEPTOR ANTAGONISTS |
| OA11558A (en) * | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| WO2002070490A1 (en) | 2001-03-08 | 2002-09-12 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
| EP1370521B1 (en) | 2001-03-22 | 2007-12-19 | Glaxo Group Limited | Formanilide derivatives as beta2-adrenoreceptor agonists |
| UA77656C2 (en) * | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| PL211953B1 (pl) | 2001-09-14 | 2012-07-31 | Glaxo Group Ltd | Pochodna fenetanoloaminy, zawierający ją środek farmaceutyczny i zastosowanie pochodnej fenetanoloaminy |
| TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| US7271197B2 (en) | 2002-04-25 | 2007-09-18 | Glaxo Group Limited | Phenethanolamine derivatives |
| AR040661A1 (es) * | 2002-07-26 | 2005-04-13 | Theravance Inc | Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2 |
| TW200510277A (en) | 2003-05-27 | 2005-03-16 | Theravance Inc | Crystalline form of β2-adrenergic receptor agonist |
| US8501994B2 (en) * | 2007-08-28 | 2013-08-06 | Sunovion Pharmaceuticals Inc. | Acetamide stereoisomer |
-
2004
- 2004-05-17 TW TW093113868A patent/TW200510277A/zh unknown
- 2004-05-24 AR ARP040101794A patent/AR045317A1/es unknown
- 2004-05-26 CA CA002525839A patent/CA2525839A1/en not_active Abandoned
- 2004-05-26 JP JP2006533430A patent/JP2007500233A/ja active Pending
- 2004-05-26 KR KR1020057022542A patent/KR20060017616A/ko not_active Ceased
- 2004-05-26 US US10/854,405 patent/US7557247B2/en not_active Expired - Lifetime
- 2004-05-26 AU AU2004243304A patent/AU2004243304A1/en not_active Abandoned
- 2004-05-26 NZ NZ543355A patent/NZ543355A/en unknown
- 2004-05-26 MX MXPA05012678A patent/MXPA05012678A/es unknown
- 2004-05-26 RU RU2005140652/04A patent/RU2005140652A/ru not_active Application Discontinuation
- 2004-05-26 BR BRPI0410705-5A patent/BRPI0410705A/pt not_active IP Right Cessation
- 2004-05-26 EP EP04753431A patent/EP1641744A2/en not_active Ceased
- 2004-05-26 WO PCT/US2004/016602 patent/WO2004106279A2/en not_active Ceased
- 2004-05-26 CN CNB200480014438XA patent/CN100528835C/zh not_active Expired - Fee Related
-
2005
- 2005-10-31 IS IS8111A patent/IS8111A/is unknown
- 2005-11-21 MA MA28612A patent/MA27779A1/fr unknown
- 2005-12-12 ZA ZA200510104A patent/ZA200510104B/xx unknown
- 2005-12-22 CO CO05129154A patent/CO5650226A2/es not_active Application Discontinuation
- 2005-12-22 NO NO20056132A patent/NO20056132L/no not_active Application Discontinuation
-
2007
- 2007-01-16 US US11/654,117 patent/US20070155990A1/en not_active Abandoned
-
2009
- 2009-05-13 US US12/465,350 patent/US7772434B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007500233A5 (enExample) | ||
| RU2005140652A (ru) | Кристаллическая форма агониста бетта2-адренергического рецептора | |
| JP2005533860A5 (enExample) | ||
| JP2008513358A5 (enExample) | ||
| JP2007518738A5 (enExample) | ||
| JP2022068321A5 (enExample) | ||
| HRP20100035T1 (hr) | Kristalni oblici bifenilnog spoja | |
| CN100491342C (zh) | 结晶β2肾上腺素能受体激动剂 | |
| JP2006528242A5 (enExample) | ||
| ES2293530T3 (es) | Derivados de sulfonamidas para el tratamiento de enfermedades. | |
| ES2320994T3 (es) | Derivados de la quinolina-2-ona para el tratamiento de enfermedades de las vias respiratorias. | |
| JP2012533550A5 (enExample) | ||
| HRP20130192T1 (hr) | Kristalni oblik bifenilnog spoja | |
| CN105025897A (zh) | 具有β2肾上腺素能受体激动剂和M3毒蕈碱受体拮抗剂两种活性的2-氨基-1-羟乙基-8-羟基喹啉-2(1H)-酮衍生物的盐 | |
| JP2016527220A5 (enExample) | ||
| JP2004514739A (ja) | 有機化合物 | |
| JP2008501705A5 (enExample) | ||
| HRP20151338T1 (hr) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze mastocita | |
| HRP20171614T1 (hr) | Heterociklički spojevi, lijekovi koji sadrže te spojeve, njihova primjena i postupci za njihovu proizvodnju | |
| TWI455938B (zh) | 碳酸啶衍生物及其醫藥組成物 | |
| JP2012503668A5 (enExample) | ||
| JP2002517438A (ja) | 咳の治療のための組成物及び方法 | |
| JP4455760B2 (ja) | 特定の薬物の硝酸エステル及び硝酸塩 | |
| JPS62228016A (ja) | 非−白金抗癌薬によりひき起こされる嘔吐の軽減用治療剤 | |
| JP2013516475A5 (enExample) |